Preliminary report of a controlled trial of MTH-68/B® virus vaccine treatment in acute B and C hepatitis

A phase II study

Laszlo K. Csatary, L. Telegdy, Péter Gergely, Bela Bodey, Tibor Bakács

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Eighty four patients with viral hepatitis attributed to infection with hepatitis B virus (HBV) (n = 43) or hepatitis C virus (HCV) (n = 41) were included in this study employing the MTH-68/B® vaccine, an attenuated variant of Bursal Disease Virus. Twenty of the 43 patients in the HBV group, and 22 of the 41 HCV patients were treated with MTH-68/B®. The remaining patients received conventional therapy. Significantly more patients progressed into active chronic hepatitis on conventional therapy (13% of HBV and 26% of HCV cases respectively) than in the vaccine treated groups (0% and 9%). Relapses occured less frequently in the vaccine treated groups (5% of HBV and 32% of HCV) than in the control groups (9% and 79%), while remissions within one month of treatment were observed more often in the vaccine treated groups (both 50% respectively) than in the control groups (26% of HBV and 21% of HCV patients respectively). The duration of hepatitis was also considerably shortened by MTH-68/B® treatment in both HBV (from 7.5 ± 3.7 to 5.9 ± 3.0 weeks) and HCV patient groups (from 8.9 ± 7.4 to 5.3 ± 4.4 weeks). The data presented suggest that attenuated, non-pathogenic viruses may be of significant benefit for patients with viral hepatitis B and C infections.

Original languageEnglish
Pages (from-to)1279-1282
Number of pages4
JournalAnticancer Research
Volume18
Issue number2 B
Publication statusPublished - Mar 1998

Fingerprint

Cercopithecine Herpesvirus 1
Hepatitis C
Hepatitis B
Vaccines
Hepatitis B virus
Hepacivirus
Therapeutics
Hepatitis
Attenuated Vaccines
Control Groups
hepatitis vaccine MTH 68-B
Virus Diseases
Chronic Hepatitis
Infection
Viruses
Recurrence

Keywords

  • Acute viral hepatitis
  • Bursal disease virus (BDV)
  • Hepatitis B virus (HBV)
  • Hepatitis C virus (HCV)
  • Hepatocellular carcinoma (HCC)
  • Phase II study
  • Virus vaccine therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Preliminary report of a controlled trial of MTH-68/B® virus vaccine treatment in acute B and C hepatitis : A phase II study. / Csatary, Laszlo K.; Telegdy, L.; Gergely, Péter; Bodey, Bela; Bakács, Tibor.

In: Anticancer Research, Vol. 18, No. 2 B, 03.1998, p. 1279-1282.

Research output: Contribution to journalArticle

Csatary, Laszlo K. ; Telegdy, L. ; Gergely, Péter ; Bodey, Bela ; Bakács, Tibor. / Preliminary report of a controlled trial of MTH-68/B® virus vaccine treatment in acute B and C hepatitis : A phase II study. In: Anticancer Research. 1998 ; Vol. 18, No. 2 B. pp. 1279-1282.
@article{30cad5eb83fa4adca6f1b08c6b2187b7,
title = "Preliminary report of a controlled trial of MTH-68/B{\circledR} virus vaccine treatment in acute B and C hepatitis: A phase II study",
abstract = "Eighty four patients with viral hepatitis attributed to infection with hepatitis B virus (HBV) (n = 43) or hepatitis C virus (HCV) (n = 41) were included in this study employing the MTH-68/B{\circledR} vaccine, an attenuated variant of Bursal Disease Virus. Twenty of the 43 patients in the HBV group, and 22 of the 41 HCV patients were treated with MTH-68/B{\circledR}. The remaining patients received conventional therapy. Significantly more patients progressed into active chronic hepatitis on conventional therapy (13{\%} of HBV and 26{\%} of HCV cases respectively) than in the vaccine treated groups (0{\%} and 9{\%}). Relapses occured less frequently in the vaccine treated groups (5{\%} of HBV and 32{\%} of HCV) than in the control groups (9{\%} and 79{\%}), while remissions within one month of treatment were observed more often in the vaccine treated groups (both 50{\%} respectively) than in the control groups (26{\%} of HBV and 21{\%} of HCV patients respectively). The duration of hepatitis was also considerably shortened by MTH-68/B{\circledR} treatment in both HBV (from 7.5 ± 3.7 to 5.9 ± 3.0 weeks) and HCV patient groups (from 8.9 ± 7.4 to 5.3 ± 4.4 weeks). The data presented suggest that attenuated, non-pathogenic viruses may be of significant benefit for patients with viral hepatitis B and C infections.",
keywords = "Acute viral hepatitis, Bursal disease virus (BDV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Hepatocellular carcinoma (HCC), Phase II study, Virus vaccine therapy",
author = "Csatary, {Laszlo K.} and L. Telegdy and P{\'e}ter Gergely and Bela Bodey and Tibor Bak{\'a}cs",
year = "1998",
month = "3",
language = "English",
volume = "18",
pages = "1279--1282",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "2 B",

}

TY - JOUR

T1 - Preliminary report of a controlled trial of MTH-68/B® virus vaccine treatment in acute B and C hepatitis

T2 - A phase II study

AU - Csatary, Laszlo K.

AU - Telegdy, L.

AU - Gergely, Péter

AU - Bodey, Bela

AU - Bakács, Tibor

PY - 1998/3

Y1 - 1998/3

N2 - Eighty four patients with viral hepatitis attributed to infection with hepatitis B virus (HBV) (n = 43) or hepatitis C virus (HCV) (n = 41) were included in this study employing the MTH-68/B® vaccine, an attenuated variant of Bursal Disease Virus. Twenty of the 43 patients in the HBV group, and 22 of the 41 HCV patients were treated with MTH-68/B®. The remaining patients received conventional therapy. Significantly more patients progressed into active chronic hepatitis on conventional therapy (13% of HBV and 26% of HCV cases respectively) than in the vaccine treated groups (0% and 9%). Relapses occured less frequently in the vaccine treated groups (5% of HBV and 32% of HCV) than in the control groups (9% and 79%), while remissions within one month of treatment were observed more often in the vaccine treated groups (both 50% respectively) than in the control groups (26% of HBV and 21% of HCV patients respectively). The duration of hepatitis was also considerably shortened by MTH-68/B® treatment in both HBV (from 7.5 ± 3.7 to 5.9 ± 3.0 weeks) and HCV patient groups (from 8.9 ± 7.4 to 5.3 ± 4.4 weeks). The data presented suggest that attenuated, non-pathogenic viruses may be of significant benefit for patients with viral hepatitis B and C infections.

AB - Eighty four patients with viral hepatitis attributed to infection with hepatitis B virus (HBV) (n = 43) or hepatitis C virus (HCV) (n = 41) were included in this study employing the MTH-68/B® vaccine, an attenuated variant of Bursal Disease Virus. Twenty of the 43 patients in the HBV group, and 22 of the 41 HCV patients were treated with MTH-68/B®. The remaining patients received conventional therapy. Significantly more patients progressed into active chronic hepatitis on conventional therapy (13% of HBV and 26% of HCV cases respectively) than in the vaccine treated groups (0% and 9%). Relapses occured less frequently in the vaccine treated groups (5% of HBV and 32% of HCV) than in the control groups (9% and 79%), while remissions within one month of treatment were observed more often in the vaccine treated groups (both 50% respectively) than in the control groups (26% of HBV and 21% of HCV patients respectively). The duration of hepatitis was also considerably shortened by MTH-68/B® treatment in both HBV (from 7.5 ± 3.7 to 5.9 ± 3.0 weeks) and HCV patient groups (from 8.9 ± 7.4 to 5.3 ± 4.4 weeks). The data presented suggest that attenuated, non-pathogenic viruses may be of significant benefit for patients with viral hepatitis B and C infections.

KW - Acute viral hepatitis

KW - Bursal disease virus (BDV)

KW - Hepatitis B virus (HBV)

KW - Hepatitis C virus (HCV)

KW - Hepatocellular carcinoma (HCC)

KW - Phase II study

KW - Virus vaccine therapy

UR - http://www.scopus.com/inward/record.url?scp=0031803061&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031803061&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 1279

EP - 1282

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 2 B

ER -